Table 1:
Known AhR ligands affecting the skeletal and immune systems
| Compound | Reference |
|---|---|
| Agonists | |
| TCDD | (Herlin, Finnila et al. 2013, Iqbal, Sun et al. 2013, Tong, Niu et al. 2017, Fader, Nault et al. 2018) |
| BaP | (Iqbal, Sun et al. 2013, Zhou, Jiang et al. 2017, An, Shi et al. 2020) |
| Kynurenine | (Kim, Hamrick et al. 2019, Eisa, Reddy et al. 2020) |
| Kynurenic acid | (DiNatale, Murray et al. 2010) |
| FICZ | (Oberg, Bergander et al. 2005) |
| 3MC | (Naruse, Otsuka et al. 2004, Yu, Kondo et al. 2014, Yu, Pang et al. 2015) |
| Tetrandrine | (Jia, Tao et al. 2019) |
| Norisoboldine | (Wei, Lv et al. 2015, Lv, Wang et al. 2018) |
| PCB126 | (Lee and Yang 2012) |
| Lipoxin A4 | (Schaldach, Riby et al. 1999, Liu, Guan et al. 2017) |
| Leflunomide | (Liang, Li et al. 2020) |
| Serotonin | (Nieto, Rayo et al. 2020) |
| 4-Hydroxytamoxifen | (DuSell, Nelson et al. 2010) |
| Sinomenine | (Tong, Yuan et al. 2016) |
| Antagonists | |
| BAY 2416964 | (Lu, Liu et al. 2022) |
| CH-223191 | (Cui, Feng et al. 2020) |
| 3’4’DMF | (Kido, Fujihara et al. 2014) |
| GNF351 | (Watson, Nordberg et al. 2019) |
| α-naphthoflavone | (Cedervall, Lind et al. 2015) |